UBS Group
ZOM

UBS Group’s Zomedica Corp. ZOM Stock Holding History

UBS Group’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,935,437
Closed -$472K – 11074
2024
Q4 		$472K Buy
3,935,437
+3,890,909
+8,738% +$490K ﹤0.01% 5888
2024
Q3 		$6.1K Sell
44,528
-27,939
-39% -$3.92K ﹤0.01% 7994
2024
Q2 		$10.6K Sell
72,467
-148,455
-67% -$22.2K ﹤0.01% 7682
2024
Q1 		$32.3K Buy
+220,922
New +$30.9K ﹤0.01% 6704
2023
Q4 		– Sell
-18,924
Closed -$3.16K – 10583
2023
Q3 		$3.16K Buy
18,924
+15,608
+471% +$3.03K ﹤0.01% 7602
2023
Q2 		$663 Sell
3,316
-17,057
-84% -$3.46K ﹤0.01% 8145
2023
Q1 		$4.32K Buy
+20,373
New +$5K ﹤0.01% 8205
2022
Q4 		– Sell
-210,693
Closed -$44K – 12005
2022
Q3 		$44K Buy
210,693
+85,736
+69% +$22.7K ﹤0.01% 6490
2022
Q2 		$27K Sell
124,957
-75,043
-38% -$19.1K ﹤0.01% 6542
2022
Q1 		$67K Buy
200,000
+134,984
+208% +$44.2K ﹤0.01% 6224
2021
Q4 		$20K Buy
65,016
+1,805
+3% +$813 ﹤0.01% 7882
2021
Q3 		$33K Sell
63,211
-353,220
-85% -$208K ﹤0.01% 6682
2021
Q2 		$347K Buy
416,431
+404,144
+3,289% +$377K ﹤0.01% 4983
2021
Q1 		$20K Buy
12,287
+3,592
+41% +$5.87K ﹤0.01% 7423
2020
Q4 		$2K Sell
8,695
-96,944
-92% -$12.4K ﹤0.01% 8180
2020
Q3 		$12K Buy
105,639
+50,665
+92% +$6.98K ﹤0.01% 6737
2020
Q2 		$13K Buy
54,974
+4,727
+9% +$900 ﹤0.01% 6874
2020
Q1 		$10K Buy
50,247
+23,808
+90% +$5.48K ﹤0.01% 6960
2019
Q4 		$9K Sell
26,439
-36,675
-58% -$12.3K ﹤0.01% 7369
2019
Q3 		$23K Buy
63,114
+20,555
+48% +$6.38K ﹤0.01% 6667
2019
Q2 		$10K Buy
42,559
+34,959
+460% +$10.6K ﹤0.01% 7102
2019
Q1 		$3K Sell
7,600
-13,245
-64% -$11.7K ﹤0.01% 7385
2018
Q4 		$26K Buy
20,845
+7,673
+58% +$12.2K ﹤0.01% 6601
2018
Q3 		$25K Buy
13,172
+3,677
+39% +$7.87K ﹤0.01% 6679
2018
Q2 		$21K Buy
9,495
+9,446
+19,278% +$19K ﹤0.01% 6672
2018
Q1 		$0 Sell
49
-3,815
-99% -$7.83K ﹤0.01% 8345
2017
Q4 		$8K Buy
+3,864
New +$8.58K ﹤0.01% 7183

Other funds holding ZOM

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
GJIA
Glass Jacobson Investment Advisors Owings Mills, Maryland $290M AUM 17.7% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

UBS Group's ZOM Position: Q1 2025 in Review

UBS Group sold out of Zomedica Corp. (ZOM) in Q1 2025, closing a stake of 3,935,437 shares — an estimated $472K sold.

UBS Group first reported a position in ZOM in Q4 2017 and held it in 27 quarters. The position peaked at $472K in Q4 2024. 23 funds tracked by Wall St. Rank hold ZOM as of Q1 2025.

  • UBS Group reported no remaining Zomedica Corp. position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 3,935,437 Zomedica Corp. shares in Q1 2025, an estimated $472K.
  • UBS Group first reported a position in Zomedica Corp. in Q4 2017 and held it in 27 quarters.
  • UBS Group's Zomedica Corp. position peaked at $472K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.